Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection

Abstract New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV pro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases 2021-02, Vol.72 (3), p.486-489
Hauptverfasser:	Stalter, Randy M, Baeten, Jared M, Donnell, Deborah, Spinelli, Matthew A, Glidden, David V, Rodrigues, Warren C, Wang, Guohong, Vincent, Michael, Mugo, Nelly, Mujugira, Andrew, Marzinke, Mark, Hendrix, Craig, Gandhi, Monica
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - therapeutic use Emtricitabine - therapeutic use HIV HIV Infections - drug therapy HIV Infections - prevention & control Humans Immunoassay Medication Adherence Pre-Exposure Prophylaxis Tenofovir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract New tools are needed to support pre-exposure prophylaxis (PrEP) adherence for human immunodeficiency virus (HIV) prevention, including those that enable real-time feedback. In a large, completed PrEP trial, adequate urine tenofovir levels measured using a novel immunoassay predicted HIV protection and showed good sensitivity and specificity for detectable plasma tenofovir.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/ciaa785